Brandes Investment Partners 13F: Adds $12M to Pfizer (PFE) Stake

Brandes Investment Partners boosted its position in Pfizer Inc. (NYSE: PFE), adding 478,043 shares during the latest reporting period. This move increased its stake by 5.54%, bringing its total holdings to 9,107,225 shares, valued at approximately $238.7 million, according to the latest Form 13F filing with the SEC.

What Changed in Brandes Investment Partners' Pfizer Position

Brandes Investment Partners previously held 8,629,182 shares of Pfizer and raised its holdings by 478,043 shares, a 5.54% increase. The firm's total stake in Pfizer now stands at 9,107,225 shares, reflecting a strong vote of confidence in the pharmaceutical giant.

Other Institutional Activity in Pfizer

BlackRock, Inc. increased its Pfizer holdings by 5,195,022 shares, ending with 498,257,550 shares valued at $13.99 billion. Vanguard Capital Management LLC maintained its position with 369,430,012 shares worth about $10.37 billion. State Street Corp added 1,144,701 shares, bringing its total to 301,589,865 shares valued at $8.47 billion. Geode Capital Management, LLC also grew its stake by 3,369,661 shares, holding 133,561,742 shares valued at $3.74 billion.

Pfizer Inc. Stock Down 11.9%

Shares of NYSE:PFE are trading near $26.21. Pfizer has a market cap of $149.4 billion, with a P/E ratio of 20.01 and a forward P/E of 9.26. The stock's beta is 0.295, indicating lower volatility compared to the market. Pfizer's 52-week low is $23.11, and its high is $28.75. The 50-day moving average is $26.40, and the 200-day moving average is $25.86. The company's current ratio is 1.247, with a quick ratio of 0.852 and a debt-to-equity ratio of 71.602.

Recent Earnings

Pfizer reported revenue of $63.32 billion, with a revenue growth of 5.4%. The net margin is 11.83%, and the return on equity is 8.31%. Earnings per share stand at $1.31. The company is scheduled to release its next earnings on July 29, 2026.

Dividend

Pfizer offers an annual dividend rate of $1.72, yielding 6.56% with a payout ratio of 131.3%.

Insider Buying and Selling at Pfizer Inc.

Several insiders have been active in recent months. CEO Albert Bourla purchased 23 shares on May 29, 2026, at $26.18, and 24 shares on May 15, 2026, at $25.33. Bourla also bought 22 shares on April 30, 2026, at $26.70. Additionally, Scott Gottlieb and Shantanu Narayen each acquired 7,687 shares at $26.67 on April 23, 2026. Jennifer Damico, SVP & Controller, sold 2,000 shares on June 9, 2026, at $25.70.

Analysts Set New Price Targets

On April 29, 2026, Citigroup maintained its hold rating with a $27 price target. CICC initiated coverage on April 16, 2026, with a buy rating and a $33 target. UBS and Morgan Stanley both maintained hold ratings with targets of $27 and $28, respectively. The consensus among 27 analysts is a buy rating, with a target mean price of $29.19.

About Pfizer Inc.

Pfizer Inc., headquartered in New York, discovers and develops biopharmaceutical products. With operations spanning internal medicine, vaccines, oncology, and rare diseases, Pfizer is a major player in the healthcare sector. The company has over 75,000 employees and is led by CEO Dr. Albert Bourla.

Bottom Line

Brandes Investment Partners' increased stake in Pfizer reflects a positive outlook for the pharmaceutical company. Investors closely watch such filings for insights into fund managers' strategies, but it's important to remember that 13F filings are historical and may not represent current positions. Pfizer's ongoing financial performance and insider activity offer additional context for market participants.